News Sentiment

N1BI34 sentiment intelligence

Neurocrine Biosciences, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report RSS feed
Weighted score 50 Balanced news tone 6 relevant articles
Exchange SAO Brazil
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 45.05 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

68/100 classification confidence.

Company focus 6

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+0.4% over one week, +4.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Neurocrine Biosciences chief legal officer sells $1.79m in stock

Market Reaction

Balanced read

44/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 68/100 classification
One-week reaction 0.4% Price digesting
Trend fit Trend active 4.6% over four weeks
Fair value 28.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 0
Neutral 6
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 6
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Investing.com 2
PR Newswire 2
Investing.com Canada 1
GuruFocus 1

Event Lens

What the news is about

Classified themes
Market update 3
Regulatory and legal 1
Deals and strategy 1
Earnings 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-6 of 6